tiprankstipranks
Stryker Corporation (GB:0R2S)
LSE:0R2S

Stryker (0R2S) Share Price & Analysis

1 Followers

0R2S Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$249.55 - $363.11
Previous Close$328.48
Volume13.71K
Average Volume (3M)5.50K
Market Cap
$125.12B
Enterprise Value$135.58B
Total Cash (Recent Filing)$2.41B
Total Debt (Recent Filing)$12.87B
Price to Earnings (P/E)37.5
Beta0.81
Jul 23, 2024
Dividend Yield0.95%
Share Statistics
EPS (TTM)8.75
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume5,500
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.47
Enterprise Value/Gross Profit10.38
Enterprise Value/Ebitda25.58
Forecast
Price Target Upside16.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17

Bulls Say, Bears Say

Bulls Say
Earnings And Revenue GrowthStryker Corporation's robust organic sales growth and full-year revenue guidance raise reflect strong performance and positive expectations.
Innovation And Market ExpansionStryker's commitment to innovation and market growth is evident through its strong procedural volume growth, supported by trends such as robotic surgery adoption and demographic changes.
Margin ExpansionGross margin expansion due to positive pricing and easing cost pressures showcases Stryker's effective cost management and profitability maintenance.
Bears Say
CompetitionPotential impact from ISRG's dV5 on SYK's revenue growth appears manageable, estimated at a 30-50bps headwind.
Revenue RiskIf ISRG's dV5 systems displace SYK ORs, it could result in a loss of $50k in revenue per OR.
ValuationValuation on SYK shares remains high relative to large-cap MedTech peers.
---

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

24.94%23.14%25.42%26.49%
24.94% Insiders
25.42% Other Institutional Investors
26.49% Public Companies and
Individual Investors

0R2S FAQ

What was Stryker Corporation’s price range in the past 12 months?
Stryker Corporation lowest share price was $249.55 and its highest was $363.11 in the past 12 months.
    What is Stryker Corporation’s market cap?
    Currently, no data Available
    When is Stryker Corporation’s upcoming earnings report date?
    Stryker Corporation’s upcoming earnings report date is Jul 23, 2024 which is in 78 days.
      How were Stryker Corporation’s earnings last quarter?
      Stryker Corporation released its earnings results on Apr 30, 2024. The company reported $2.5 earnings per share for the quarter, beating the consensus estimate of $2.356 by $0.144.
        Is Stryker Corporation overvalued?
        According to Wall Street analysts Stryker Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Stryker Corporation pay dividends?
          Stryker Corporation pays a Quarterly dividend of $0.8 which represents an annual dividend yield of 0.95%. See more information on Stryker Corporation dividends here
            What is Stryker Corporation’s EPS estimate?
            Stryker Corporation’s EPS estimate is $2.79.
              How many shares outstanding does Stryker Corporation have?
              Stryker Corporation has 380,949,770 shares outstanding.
                What happened to Stryker Corporation’s price movement after its last earnings report?
                Stryker Corporation reported an EPS of $2.5 in its last earnings report, beating expectations of $2.356. Following the earnings report the stock price went down -3.233%.
                  Which hedge fund is a major shareholder of Stryker Corporation?
                  Among the largest hedge funds holding Stryker Corporation’s share is Fisher Asset Management LLC. It holds Stryker Corporation’s shares valued at 1B.
                    ---

                    Company Description

                    Stryker Corporation

                    Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.
                    ---

                    0R2S Earnings Call

                    Q1 2024
                    0:00 / 0:00
                    ---

                    0R2S Net sales Breakdown

                    57.74%57.74%42.26%
                    57.74% MedSurg and Neurotechnology
                    42.26% Orthopaedics and Spine
                    tipranks
                    ---

                    0R2S Stock 12 Months Forecast

                    Average Price Target

                    $383.57
                    ▲(16.77% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"264":"$264","407":"$407","299.75":"$299.8","335.5":"$335.5","371.25":"$371.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":406,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$406.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":383.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$383.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":364,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$364.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[264,299.75,335.5,371.25,407],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,328.48,334.44307692307694,340.40615384615387,346.3692307692308,352.3323076923077,358.29538461538465,364.2584615384616,370.22153846153844,376.18461538461537,382.1476923076923,388.1107692307692,394.07384615384615,400.0369230769231,{"y":406,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,328.48,332.71769230769235,336.9553846153846,341.19307692307694,345.4307692307692,349.66846153846154,353.90615384615387,358.14384615384614,362.38153846153847,366.61923076923074,370.85692307692307,375.0946153846154,379.33230769230767,{"y":383.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,328.48,331.2123076923077,333.9446153846154,336.6769230769231,339.40923076923076,342.14153846153846,344.87384615384616,347.60615384615386,350.33846153846156,353.07076923076926,355.8030769230769,358.5353846153846,361.2676923076923,{"y":364,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":281.897,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":274.637,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.048,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":283.934,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":280.948,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":265.34,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.142,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":295.59,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.179,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":340.174,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":352.586,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349.94,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.48,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Stryker
                    Becton Dickinson
                    Edwards Lifesciences
                    Medtronic
                    Abbott Laboratories

                    Best Analysts Covering 0R2S

                    1 Year
                    Matt MiksicBarclays
                    1 Year Success Rate
                    20/24 ratings generated profit
                    83%
                    1 Year Average Return
                    +16.22%
                    reiterated a buy rating 4 days ago
                    Copying Matt Miksic's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +16.22% per trade.
                    Popular Stocks
                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis